Post-marketing surveillance should include effects during pregnancyBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7486.308-a (Published 03 February 2005) Cite this as: BMJ 2005;330:308
- Patricia Yeargin, associate medical editor, health promotions (email@example.com)
- American Cancer Society, 1599 Clifton Road, NE, Atlanta, GA 30329
EDITOR—I agree that post-marketing surveillance of drugs is desperately needed.1 I further believe that, since information about drugs' effects during human gestation is never studied during pre-marketing, some post-marketing study of fetal effects during pregnancy should be considered.
I have seen many women's medical care neglected during pregnancy owing to fear of harming the fetus, even when there is no real evidence …